Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMISE ctDNA-guided treatment selection in oligometastatic colorectal cancer
2020-004524-41Phase 2Active
- Sponsor
- Aarhus University Hospital
- Start
- Oct 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of irinotecan, oxaliplatin, fluorouracil, folinic acid and capecitabine in colorectal cancer (CRC) (2 arms), sponsored by Aarhus University Hospital. Primary endpoint: Rate of patients free from recurrent colorectal cancer at 2 years post local treatment. Started Oct 2020; status: active.
02
Drugs
irinotecanoxaliplatinfluorouracilfolinic acidcapecitabine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2020-004524-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004524-41.